Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves

By Schmidt Stephan   Schuck Edgar   Kumar Vipul   Burkhardt Olaf   Derendorf Hartmut  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 6, 2007-06 ,pp. : 849-860

Informa Healthcare

Access to resources Recommend Favorite

Clinical Use of Ceftriaxone: A Pharmacokinetic-Pharmacodynamic Perspective on the Impact of Minimum Inhibitory Concentration and Serum Protein Binding

By Perry T.R.   Schentag J.J.  

Clinical Pharmacokinetics, Vol. 40, Iss. 9, 2001-01 ,pp. : 685-694

Adis International

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Modelling of Magnesium Plasma Concentration and Blood Pressure in Preeclamptic Women

By Lu J.  

Clinical Pharmacokinetics, Vol. 41, Iss. 13, 2002-01 ,pp. : 1105-1113

Adis International

Access to resources Recommend Favorite

Relationship Between Minimum Inhibitory Concentration and Stationary Concentration Revisited: Growth Rates and Minimum Bactericidal Concentrations

By Adis International Limited  

Clinical Pharmacokinetics, Vol. 44, Iss. 7, 2005-01 ,pp. : 767-768

Adis International

Access to resources Recommend Favorite

Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: lack of change in concentration-EEG effect relationship

By Cleton A.   Altorf B.A.   Voskuyl R.A.   Danhof M.  

European Journal of Pharmaceutical Sciences, Vol. 12, Iss. 2, 2000-12 ,pp. : 141-150

Elsevier

Access to resources Recommend Favorite